Merck & Company Inc. Common Stock (new) (MRK) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Merck & Company Inc. Common Stock (new) (MRK) is Neutral.

The composite score behind that read is +0.15, weighing +0.45 of bullish evidence against -0.27 bearish.

Merck & Company Inc. Common Stock (new) last closed at $145.60, +2.26% on the session.

Against the IVW growth benchmark the position is +1.46% over the forecast window.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 40%.

Merck & Company Inc. Common Stock (new) has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Merck & Company Inc. Common Stock (new) in the 5th percentile on valuation and the 51st percentile on return on equity, where 100 is best.

Merck & Company Inc. Common Stock (new) is classified under Health Care / Pharmaceuticals, with a market capitalisation of $351.28B.

StockMap tracks Merck & Company Inc. Common Stock (new) as the 3rd largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Merck & Company Inc. Common Stock (new) ranks 23rd of 151 in the group, against a group median of -0.08.